Bank of America spends $250 million a year on GLP-1 drugs for its employees, CEO says
Employers have grappled with soaring demand for GLP-1 drugs such as Ozempic and Wegovy, which can cost thousands of dollars per patient annually.
Bank of America's annual spend on GLP-1 drugs has reached a quarter of a billion dollars, according to its chief executive. The figure is a rare public disclosure of what employers are quietly absorbing as demand for these treatments accelerates.
The number matters less as a line item than as a signal. A company of this size does not volunteer a cost figure like that without a reason. It is a statement about the permanence of the expense, and about the employer's role in underwriting a medical trend that shows no sign of slowing.
For the labor market, the implication is straightforward. Health benefits are a fixed cost that scales with headcount, and GLP-1 coverage is becoming one of the more expensive components of that equation. Employers who offer it are making a deliberate bet that the cost is worth the retention and productivity gains. Those who do not are left competing for workers with a visible gap in their benefits package.
The disclosure also hints at the broader pricing pressure building beneath the surface of corporate health spending. When a single drug class consumes a meaningful share of a major employer's benefits budget, it invites scrutiny from finance departments and, eventually, from negotiators. The question is not whether employers will push back on price, but when and how forcefully.
For now, Bank of America's number is a benchmark. It gives other large employers a reference point for their own exposure, and it gives the market a clearer picture of how deeply GLP-1s have embedded themselves in the cost structure of American work.